综合征性遗传性胸主动脉疾病患者主动脉弓的管理
研究筛查1995年以来就诊的Marfan综合征(MFS)或Loeys-Dietz综合征(LDS)并已接受主动脉手术的患者,分析主动脉弓替换范围、主动脉夹层史及二次全主动脉弓替换(TAR)结局。结论:MFS患者择期根部修复时预防性TAR不 justified;有急性主动脉夹层(AAD)史的MFS患者约四分之一随访中需二次TAR,但二次TAR者生存不劣于未行二次TAR者;LDS预防性弓部替换证据不足。
要点
- MFS择期根部修复时不建议同期预防性全主动脉弓替换。
- 有AAD史的MFS患者约1/4随访中需二次TAR,但生存未变差。
- LDS预防性主动脉弓替换目前证据不足,无法强推荐。
核心结论
- MFS患者择期根部修复时同期预防性TAR不 justified。
- 有AAD史的MFS患者约四分之一随访中需二次TAR,二次TAR者生存不劣于未行二次TAR者。
- LDS患者预防性主动脉弓替换的现有证据不足以形成强推荐。
研究设计与样本
- 回顾性队列研究,筛查1995年以来HTAD门诊的MFS或LDS患者。
- 纳入已接受主动脉手术的MFS(n=138)和LDS(n=27)患者,共165例。
- 按主动脉弓替换范围、主动脉夹层史及二次TAR结局进行分析。
主要发现
- LDS患者初始表现为AAD 5例(19%),动脉瘤病22例(81%)。
- LDS随访中仅2例需二次TAR。
- MFS患者初始表现为AAD 41例(30%),动脉瘤病97例(70%)。
- 无初次主动脉弓替换的MFS患者中仅3%(n=3)需二次TAR。
- 有主动脉夹层史的MFS患者二次TAR显著多于无夹层史者(P=0.019)。
关键数值与推荐
- 有夹层史与无夹层史的MFS患者二次TAR率差异显著(P=0.019)。
- 二次TAR与未行二次TAR的MFS患者下游主动脉事件率无显著差异(P=0.089)。
- 二次TAR与未行二次TAR的MFS患者死亡率无显著差异(P=0.366)。
临床怎么用
- MFS择期根部修复时不应常规同期行预防性全主动脉弓替换。
- 有AAD史的MFS患者随访中需警惕二次TAR可能,但二次TAR不增加死亡风险。
- LDS患者弓部管理决策需个体化,不宜强推预防性弓部替换。
局限性
- 为单中心回顾性研究,样本以MFS为主,LDS样本量小。
- LDS患者中仅2例二次TAR,难以形成强推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to examine the evolution of the aortic arch over time in patients with HTAD. METHODS: We screened all patients with Marfan syndrome (MFS) or Loeys-Dietz syndrome (LDS) who were seen at our HTAD clinic since 1995. Patients who had undergone aortic surgery were included in the present study. Patients were analysed based on (1) extent of aortic arch replacement, (2) history of aortic dissection and (3) outcome after secondary total aortic arch replacement (TAR). RESULTS: A cohort of 260 patients was identified of whom 165 patients with MFS (n = 138) and LDS (n = 27) had already undergone aortic surgery and were included in this study. LDS: initial presentation was acute aortic dissection (AAD) in five (19%) patients, while 22 (81%) patients presented with aneurysmal disease. Only two patients required secondary TAR during follow-up. MFS: initial presentation was AAD in 41 (30%) patients, while 97 (70%) presented with aneurysmal disease. Only 3% (n = 3) of the MFS patients without primary aortic arch replacement required a secondary TAR. There was significantly more secondary TAR in MFS patients with history of aortic dissection compared to those without (P = 0.019). However, there was no significant differences in rate of downstream aortic events in MFS patients with secondary TAR compared to those without (P = 0.089). There was no significant difference in mortality in MFS patients with secondary TAR compared to those without (P = 0.366). CONCLUSIONS: Concomitant prophylactic TAR in MFS patients undergoing elective root repair is not justified. One out of four MFS patients with history of AAD will have to undergo secondary TAR during follow-up. MFS patients undergoing secondary TAR do not have worse survival compared to those without. Current data do not provide enough evidence for strong recommendations regarding the need for prophylactic aortic arch replacement in LDS patients.
引用
- Nucera M, Yildiz M, Mosbahi S, et al. Management of the aortic arch in patients with syndromic heritable thoracic aortic disease. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40581620. doi:10.1093/icvts/ivaf143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。